XBIO
Xenetic BiosciencesCOperating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
Peer overview
Protalix BioTherapeutics is the closest public mechanism comparator identified: its research-stage PRX-119 is a long-acting recombinant human DNase I candidate intended to degrade neutrophil extracellular traps. It is not an oncology-stage valuation peer because its DNase program targets broader NET-related diseases and Protalix also has commercial products, but it provides relevant evidence for DNase development and platform differentiation.
Grade position vs PLX
Rotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.

